Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

PURPOSE: To evaluate the efficacy and toxicity of pemetrexed combined with bevacizumab as second-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) and to correlate allelic variants in pemetrexed-metabolizing genes with clinical outcome. PATIENTS AND METHODS: Patients with pr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Adjei, Alex A., Mandrekar, Sumithra J., Dy, Grace K., Molina, Julian R., Adjei, Araba A., Gandara, David R., Ziegler, Katie L. Allen, Stella, Philip J., Rowland, Kendrith M., Schild, Steven E., Zinner, Ralph G.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2815996/
https://ncbi.nlm.nih.gov/pubmed/19841321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.6406
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados